Sandra Lee, PA
Physician Assistant · Fresno, CANPI 1376566968
Payments from drug & device makers
Across 171 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$579
- AbbVie$518
- Amgen$462
- Bayer$409
- Daiichi Sankyo Inc.$233
- Pfizer$219
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,931100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $579 |
| AbbVie(2 entities) | 31 | $518 |
| Amgen | 16 | $462 |
| Bayer | 13 | $409 |
| Daiichi Sankyo Inc. | 2 | $233 |
| Pfizer | 10 | $219 |
| Incyte Corporation | 8 | $202 |
| Atricure, Inc. | 3 | $173 |
| Lilly USA, LLC | 8 | $134 |
| Medtronic | 1 | $98 |
| Boston Scientific | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Philips North America LLC | 3 | $69 |
| Novo Nordisk | 4 | $64 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Biohaven Pharmaceuticals, Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| GSK | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Merck | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Novartis | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Abbott | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Smith+Nephew | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$225
- ATRICLIP LAA EXCLUSION SYSTEM$141
- OPZELURA$125
- Prolia$122
How this compares
$3,938 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $30,542 |
| FarxigaDapagliflozin Propanediol | 17 | $22,638 |
| OzempicSemaglutide | 19 | $16,742 |
| MyrbetriqMirabegron | 13 | $13,432 |
| Icosapent Ethyl | 17 | $8,120 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,569 |
| Repatha SyringeEvolocumab | 17 | $4,974 |
| Rosuvastatin Calcium | 176 | $3,144 |
| Ezetimibe | 45 | $2,006 |
| SynthroidLevothyroxine Sodium | 16 | $1,540 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,397 |
| Levothyroxine Sodium | 61 | $1,249 |
| Quetiapine Fumarate | 27 | $1,011 |
| Atorvastatin Calcium | 54 | $912 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 13 | $902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $134 | $30,54220 claims |
| AstraZenecaFarxiga | $579 | $22,63817 claims |
| Novo NordiskOzempic | $64 | $16,74219 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $13,43213 claims |
| AbbVieSynthroid | $518 | $1,54016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Fresno
- Brooke KutkaFresno$67K
- David BakerFresno$37K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.